Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.49 |
| ▸ | MAG | P20916 | 8/20 | 0.44 |
| ▸ | SELL | P14151 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17447127 | 0.89 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17448433 | 0.85 | SIGLEC7 (0.42) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16311983 | 0.84 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16311992 | 0.84 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL12451190 | 0.83 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17827374 | 0.83 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17447130 | 0.83 | SIGLEC7 (0.58) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16312001 | 0.82 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL20252453 | 0.82 | SIGLEC7 (0.61) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL20252456 | 0.82 | SIGLEC7 (0.61) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | SIGLEC7 52/4885MAG 423/4885SELL 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.